Please use this identifier to cite or link to this item:
Title: Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
Authors: Wanwisa Dejnirattisai
Piyada Supasa
Wiyada Wongwiwat
Alexander Rouvinski
Giovanna Barba-Spaeth
Thaneeya Duangchinda
Anavaj Sakuntabhai
Van Mai Cao-Lormeau
Prida Malasit
Felix A. Rey
Juthathip Mongkolsapaya
Gavin R. Screaton
Imperial College London
Mahidol University
Institut Pasteur, Paris
CNRS Centre National de la Recherche Scientifique
Thailand National Center for Genetic Engineering and Biotechnology
Institut Louis Malarde
Keywords: Immunology and Microbiology
Issue Date: 19-Aug-2016
Citation: Nature Immunology. Vol.17, No.9 (2016), 1102-1108
Abstract: © 2016 Nature America, Inc. Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barré syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.
ISSN: 15292916
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.